Update on D2E7: a fully human anti-tumour necrosis factor alpha monoclonal antibody.
Kempeni
J
J
Department of Clinical Oncology/Immunology, Knoll AG-BASF Pharma, Knollstrasse, D-67008 Ludwigshafen, Germany. joachim.kempeni@knoll-ag.de
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000628:therapy*; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D006801:Humans; D016032:Randomized Controlled Trials as Topic; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology*
D000911:Antibodies, Monoclonal; D014409:Tumor Necrosis Factor-alpha